Alzheimer's Disease Clinical Trials

35 studies are recruiting for alzheimer's disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Wake Forest Alzheimer's Disease Clinical Core

   Efforts to find treatments for AD have yielded only modest benefits, likely because longstanding AD pathological processes induce irreversible neurological compromise. These processes begin years before the onset of clinical symptoms. This possibility has been incorporated into a model describing s…

   Stage

   Not phased

   Ages

   55 and older

   Site

   Wake Forest Baptist Health, Winston-Salem, North Carolina

   Run by

   Wake Forest University Health Sciences

   See if you can join NCT03140865 on ClinicalTrials.gov

2. Retinal Imaging in Neurodegenerative Disease

   This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Run by

   Duke University

   See if you can join NCT03233646 on ClinicalTrials.gov

3. Open-label Extension Study in Participants With Early Alzheimer's Disease

   The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same …

   Stage

   Phase 2

   Ages

   50 to 85

   Site

   GSK Investigational Site, Maitland, Florida

   Locations

   33 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT07105709 on ClinicalTrials.gov

4. PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

   The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary …

   Stage

   Phase 1

   Ages

   18 to 85

   Site

   Brigham MS Center, 60 Fenwood Road, Boston, Massachusetts

   Run by

   Brigham and Women's Hospital

   See if you can join NCT02649985 on ClinicalTrials.gov

5. Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies

   The Alzheimer's Prevention Registry (www.endALZnow.org) will collect contact and demographic information on individuals. The objective is to provide information the latest news and advances in Alzheimer's prevention research, and to inform enrollees about research studies in their community. Enroll…

   Stage

   Not phased

   Ages

   18 to 110

   Site

   Banner Alzheimer's Institute, Phoenix, Arizona

   Run by

   Banner Health

   See if you can join NCT02022943 on ClinicalTrials.gov

6. Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition

   The goal of this clinical trial is to determine if a weekly delivery of insulin at short intervals lasting up to 2 hours can improve insulin sensitivity and cognition in adults with Alzheimer's Disease. It will also provide information about the safety and feasibility of this intervention. The main…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Pennington Biomedical Research Center, Baton Rouge, Louisiana

   Run by

   Pennington Biomedical Research Center

   See if you can join NCT07265323 on ClinicalTrials.gov

7. Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study

   The purpose of this study is to see if a special light treatment, called photobiomodulation, can help people with memory problems such as Mild Cognitive Impairment or Mild Dementia due to Alzheimer's disease. The light is given to the forehead using an FDA-cleared medical device. This device is cle…

   Stage

   Not phased

   Ages

   55 to 89

   Site

   CSMC, Los Angeles, California

   Run by

   Cedars-Sinai Medical Center

   See if you can join NCT07224607 on ClinicalTrials.gov

8. A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors

   Up to 25% of intensive care unit (ICU) survivors experience cognitive impairment comparable in severity to mild Alzheimer's disease and related dementias after hospital discharge. Older ICU survivors (ages 60 and older) are at highest risk for delirium and subsequent cognitive impairment, which con…

   Stage

   Not phased

   Ages

   60 and older

   Site

   University of Washington, Seattle, Washington

   Run by

   University of Washington

   See if you can join NCT06411561 on ClinicalTrials.gov

9. Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

   This clinical trial is focused on determining whether biological signatures of target engagement by a Centella asiatica water extract product administered orally for 6 weeks can be measured in comparison to placebo. This study will also assess the safety and tolerability of the Centella asiatica wa…

   Stage

   Phase 1

   Ages

   60 to 85

   Site

   Oregon Health & Science University, Portland, Oregon

   Run by

   Oregon Health and Science University

   See if you can join NCT05591027 on ClinicalTrials.gov

10. Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

    The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.

    Stage

    Not phased

    Ages

    18 and older

    Site

    The Ohio State University, Columbus, Ohio

    Run by

    Douglas Scharre

    See if you can join NCT03019757 on ClinicalTrials.gov